000095494 001__ 95494
000095494 005__ 20210902121718.0
000095494 0247_ $$2doi$$a10.3390/antiox9080718
000095494 0248_ $$2sideral$$a119566
000095494 037__ $$aART-2020-119566
000095494 041__ $$aeng
000095494 100__ $$aPerdices, Lorena
000095494 245__ $$aEpigallocatechin gallate slows retinal degeneration, reduces oxidative damage, and modifies circadian rhythms in P23H Rats
000095494 260__ $$c2020
000095494 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095494 5203_ $$aRetinitis pigmentosa (RP) includes a group of genetic disorders that involve the loss of visual function due to mutations mainly in photoreceptors but also in other retinal cells. Apoptosis, retinal disorganization, and inflammation are common in the progression of the disease. Epigallocatechin gallate (EGCG) has been proved as beneficial in different eye diseases. Pigmented heterozygous P23H rat was used as an animal model of RP. Visual function was assessed by optomotor and electroretinogram (ERG) and circadian rhythms were evaluated by telemetry. Hepatic oxidative damage and antioxidant defenses were assessed using biochemical tests. The visual function of the EGCG P23H group was preserved, with a deterioration in the activity period and lower values in the interdaily stability parameter. Control rats treated with EGCG were less active than the sham group. EGCG increased antioxidant levels in P23H rats but reduced total hepatic antioxidant capacity by almost 42% in control rats compared to the sham group. We conclude that treatment with EGCG improves visual function and antioxidant status in P23H rats but diminishes antioxidant defenses in wild-type control animals, and slightly worsens activity circadian rhythms. Further studies are necessary to clarify the beneficial effects in disease conditions and in healthy organisms.
000095494 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B08-17R$$9info:eu-repo/grantAgreement/ES/ISCIII/PI13-01124$$9info:eu-repo/grantAgreement/ES/ISCIII/RETICS-FEDER-RD16-0008-0016$$9info:eu-repo/grantAgreement/ES/MINECO-FEDER/BFU2015-67139-R
000095494 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000095494 590__ $$a6.312$$b2020
000095494 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b60 / 297 = 0.202$$c2020$$dQ1$$eT1
000095494 591__ $$aFOOD SCIENCE & TECHNOLOGY$$b11 / 144 = 0.076$$c2020$$dQ1$$eT1
000095494 591__ $$aCHEMISTRY, MEDICINAL$$b6 / 63 = 0.095$$c2020$$dQ1$$eT1
000095494 592__ $$a1.066$$b2020
000095494 593__ $$aBiochemistry$$c2020$$dQ2
000095494 593__ $$aCell Biology$$c2020$$dQ2
000095494 593__ $$aPhysiology$$c2020$$dQ2
000095494 593__ $$aMolecular Biology$$c2020$$dQ2
000095494 593__ $$aClinical Biochemistry$$c2020$$dQ2
000095494 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000095494 700__ $$0(orcid)0000-0003-2656-6750$$aFuentes-Broto, Lorena$$uUniversidad de Zaragoza
000095494 700__ $$0(orcid)0000-0002-9250-9060$$aSegura, Francisco$$uUniversidad de Zaragoza
000095494 700__ $$aCuenca, Nicolás
000095494 700__ $$0(orcid)0000-0003-2710-1875$$aOrduna-Hospital, Elvira$$uUniversidad de Zaragoza
000095494 700__ $$0(orcid)0000-0003-0349-9997$$aPinilla, Isabel$$uUniversidad de Zaragoza
000095494 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000095494 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000095494 7102_ $$12002$$2647$$aUniversidad de Zaragoza$$bDpto. Física Aplicada$$cÁrea Óptica
000095494 773__ $$g9, 8 (2020), 718 1-21$$pAntioxidants$$tAntioxidants$$x2076-3921
000095494 8564_ $$s4628939$$uhttps://zaguan.unizar.es/record/95494/files/texto_completo.pdf$$yVersión publicada
000095494 8564_ $$s499261$$uhttps://zaguan.unizar.es/record/95494/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000095494 909CO $$ooai:zaguan.unizar.es:95494$$particulos$$pdriver
000095494 951__ $$a2021-09-02-09:26:16
000095494 980__ $$aARTICLE